News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
824,299 Results
Type
Article (85264)
Company Profile (622)
Press Release (738413)
Section
Business (231846)
Career Advice (4090)
Deals (39621)
Drug Delivery (106)
Drug Development (90425)
Employer Resources (192)
FDA (17886)
Job Trends (17246)
News (394603)
Policy (39583)
Tag
Academia (2973)
Africa (1262)
Alliances (56333)
Alzheimer's disease (1242)
Approvals (17793)
Arizona (210)
Artificial intelligence (86)
Asia (48996)
Australia (8615)
Bankruptcy (392)
Best Places to Work (12247)
Biotechnology (437)
C2C Services and Suppliers (95111)
California (1987)
Canada (934)
Cancer (525)
Career advice (3497)
Cell therapy (140)
China (154)
Clinical research (70412)
Collaboration (150)
Colorado (80)
Compensation (82)
Connecticut (81)
COVID-19 (2753)
Cystic fibrosis (77)
Data (296)
Diabetes (91)
Diagnostics (6496)
Drug pricing (82)
Earnings (93521)
Employer resources (162)
Europe (111998)
Events (124972)
Executive appointments (152)
FDA (18100)
Florida (269)
Funding (149)
Gene therapy (106)
GLP-1 (618)
Government (5007)
Healthcare (20647)
Hotbed/Location (534575)
Illinois (319)
Indiana (160)
Infectious disease (2784)
Inflammatory bowel disease (102)
Interviews (805)
IPO (17484)
Job creations (5172)
Job search strategy (2849)
Kansas (100)
Layoffs (467)
Legal (10012)
Lung cancer (125)
Manufacturing (100)
Maryland (426)
Massachusetts (1694)
Medical device (14261)
Medtech (14266)
Mergers & acquisitions (21953)
Metabolic disorders (295)
Michigan (135)
Minnesota (235)
Neuroscience (1404)
New Jersey (605)
New York (606)
NextGen Class of 2024 (7622)
Non-profit (5052)
North Carolina (698)
Northern California (837)
Obesity (176)
Ohio (110)
Opinion (234)
Patents (75)
Pennsylvania (587)
People (63706)
Pharmaceutical (119)
Phase I (21619)
Phase II (30568)
Phase III (23100)
Pipeline (110)
Podcasts (75)
Postmarket research (3532)
Preclinical (9762)
Press Release (72)
Rare diseases (140)
Real estate (7361)
Recruiting (72)
Regulatory (25587)
Research institute (2633)
Resumes & cover letters (645)
South America (1641)
Southern California (759)
Startups (4271)
Texas (263)
United States (9238)
Vaccines (563)
Washington State (277)
Weight loss (168)
Date
Today (76)
Last 7 days (700)
Last 30 days (2414)
Last 365 days (40037)
2024 (27961)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51341)
2018 (39126)
2017 (37193)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
There are 824,299 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report
Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.
September 17, 2024
·
2 min read
·
Kate Goodwin
Weight loss
Obesity Pill Races Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
September 17, 2024
·
4 min read
·
Nick Paul Taylor
Gene Therapy
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.
September 17, 2024
·
2 min read
·
Annalee Armstrong
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
·
2 min read
·
Tristan Manalac
GLP-1
GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study
In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis.
September 17, 2024
·
2 min read
·
Tristan Manalac
Phase III
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
September 17, 2024
·
2 min read
·
Tristan Manalac
RSV
Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of RSV Antibody
The newly approved filling line will be able to provide both 50-mg and 100-mg doses of the respiratory syncytial virus antibody Beyfortus to help meet demand ahead of the 2024/2025 RSV season.
September 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.
September 17, 2024
·
8 min read
Press Releases
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million
September 17, 2024
·
3 min read
Press Releases
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
September 17, 2024
·
12 min read
1 of 82,430
Next
